News

News and Press Releases
CFTR Modulators New England Journal of Medicine Publishes Study about VX-770 — A Promising Drug That Targets Underlying Defect in CF

The New England Journal of Medicine, the world's most influential and widely read medical periodical, features a study this week about a Phase 2 clinical trial of VX-770, an oral drug in development that targets the root cause of cystic fibrosis.

Nov. 17, 2010 | 3 min read
Research FDA Approves Third Pancreatic Enzyme Product: Pancreaze Delayed-Release Capsules

The U.S. Food and Drug Administration (FDA) has approved PancreazeTM delayed-release capsules, a pancreatic enzyme replacement therapy. This is the third such product to receive approval. Pancreaze is manufactured by Johnson & Johnson.

April 15, 2010 | 1 min read
Research CF Foundation Plays Important Role in Bringing New Inhaled Antibiotic Cayston to Patients

The U.S. Food and Drug Administration approved an important new inhaled antibiotic called Cayston® (aztreonam for inhalation solution) today for the treatment of cystic fibrosis (CF). 

Feb. 22, 2010 | 3 min read